Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR300 injection for prevention of relapse after allogeneic HSCT in acute myeloid leukemia (phase I/II)
CTR20241346Phase 2Active
- Sponsor
- Zhongsheng Suyuan
- Start
- Oct 2024
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of NCR-300 in acute myeloid leukemia (AML), sponsored by Zhongsheng Suyuan. Started Oct 2024; status: active.
02
Drugs
NCR-300
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20241346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241346.